{"id":{"repo_id":"dialnet","oai_identifier":"oai:dialnet.unirioja.es:TES0000023168"},"canonical_url":"https://search.dev.ndltd.org/etd/dialnet/oai:dialnet.unirioja.es:TES0000023168","repository":{"repo_id":"dialnet","name":"Dialnet","base_url":"https://dialnet.unirioja.es/oaites/OAIHandler"},"display":{"title":"Structure-guided Cancer Vaccines based on Glycopeptides Supported on Diverse Nanoparticles","abstract":"Cancer is a worldwide problem and various cancer therapies are emerging as potential solutions. Among these cancer therapies, a very attractive strategy is that of therapeutic cancer vaccines, which can use tumor-associated peptide fragments that can induce an immune response. In this thesis, we focus on the peptide sequence of MUC1, a glycoprotein presents on the surface of epithelial cells, which leaves simple carbohydrates, and the backbone of the peptide exposed in cancer cells due to aberrant glycosylation. In nature, this exposure to the immune system doesn't trigger a sufficient immune response, due to elusive mechanisms of the cancer cells. For this reason, the core of the present work is to design MUC1-based peptide vaccines modifying the backbone with non-natural mimetics or using different carrier systems to present the antigen to the immune system. In this thesis are presented two vaccines conjugated that have been shown to elicit high immune response utilizing in one case β-amino acid substitutions in the peptide backbone and utilizing as carrier gold nanoparticles, and a second one utilizing an epitope of the MUC1 along with a T helper epitope conjugated to silica nanoparticles. We also present in this work the synthesis of different MUC1 glycopeptides with modifications in the Arg residue and their comparison in terms of affinity towards the SM3 anti-MUC1 monoclonal antibody to select a vaccine candidate among them.","abstract_html":"Cancer is a worldwide problem and various cancer therapies are emerging as potential solutions. Among these cancer therapies, a very attractive strategy is that of therapeutic cancer vaccines, which can use tumor-associated peptide fragments that can induce an immune response. In this thesis, we focus on the peptide sequence of MUC1, a glycoprotein presents on the surface of epithelial cells, which leaves simple carbohydrates, and the backbone of the peptide exposed in cancer cells due to aberrant glycosylation. In nature, this exposure to the immune system doesn't trigger a sufficient immune response, due to elusive mechanisms of the cancer cells. For this reason, the core of the present work is to design MUC1-based peptide vaccines modifying the backbone with non-natural mimetics or using different carrier systems to present the antigen to the immune system. In this thesis are presented two vaccines conjugated that have been shown to elicit high immune response utilizing in one case β-amino acid substitutions in the peptide backbone and utilizing as carrier gold nanoparticles, and a second one utilizing an epitope of the MUC1 along with a T helper epitope conjugated to silica nanoparticles. We also present in this work the synthesis of different MUC1 glycopeptides with modifications in the Arg residue and their comparison in terms of affinity towards the SM3 anti-MUC1 monoclonal antibody to select a vaccine candidate among them.","abstract_has_math":false,"creators":["Suárez García, Oscar"],"institution":"Universidad de La Rioja (España)","degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":["Busto Sancirián, Jesús Héctor (Universidad de La Rioja)","García Martín, Fayna M. (Universidad de La Rioja)"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2025,"date_issued":"2025","date_published":"2025","updated_at":"2026-07-24T06:27:07Z","subjects":[],"languages":["eng"],"rights":["LICENCIA DE USO: Los documentos a texto completo incluidos en Dialnet son de acceso libre y propiedad de sus autores y/o editores. Por tanto, cualquier acto de reproducción, distribución, comunicación pública y/o transformación total o parcial requiere el consentimiento expreso y escrito de aquéllos. Cualquier enlace al texto completo de estos documentos deberá hacerse a través de la URL oficial de éstos en Dialnet. Más información: https://dialnet.unirioja.es/info/derechosOAI | INTELLECTUAL PROPERTY RIGHTS STATEMENT: Full text documents hosted by Dialnet are protected by copyright and/or related rights. This digital object is accessible without charge, but its use is subject to the licensing conditions set by its authors or editors. Unless expressly stated otherwise in the licensing conditions, you are free to linking, browsing, printing and making a copy for your own personal purposes. All other acts of reproduction and communication to the public are subject to the licensing conditions expressed by editors and authors and require consent from them. Any link to this document should be made using its official URL in Dialnet. More info: https://dialnet.unirioja.es/info/derechosOAI"],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"https://dialnet.unirioja.es/servlet/oaites?codigo=362824","outbound_label":"Repository record","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Busto Sancirián, Jesús Héctor (Universidad de La Rioja)","García Martín, Fayna M. (Universidad de La Rioja)"]},{"key":"dc:creator","label":"Author","values":["Suárez García, Oscar"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2025"]},{"key":"dc:publisher","label":"Institution","values":["Universidad de La Rioja (España)"]},{"key":"dc:type","label":"Dc Type","values":["text (thesis)"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["eng"]},{"key":"dc:rights","label":"Dc Rights","values":["LICENCIA DE USO: Los documentos a texto completo incluidos en Dialnet son de acceso libre y propiedad de sus autores y/o editores. Por tanto, cualquier acto de reproducción, distribución, comunicación pública y/o transformación total o parcial requiere el consentimiento expreso y escrito de aquéllos. Cualquier enlace al texto completo de estos documentos deberá hacerse a través de la URL oficial de éstos en Dialnet. Más información: https://dialnet.unirioja.es/info/derechosOAI | INTELLECTUAL PROPERTY RIGHTS STATEMENT: Full text documents hosted by Dialnet are protected by copyright and/or related rights. This digital object is accessible without charge, but its use is subject to the licensing conditions set by its authors or editors. Unless expressly stated otherwise in the licensing conditions, you are free to linking, browsing, printing and making a copy for your own personal purposes. All other acts of reproduction and communication to the public are subject to the licensing conditions expressed by editors and authors and require consent from them. Any link to this document should be made using its official URL in Dialnet. More info: https://dialnet.unirioja.es/info/derechosOAI"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://dialnet.unirioja.es/servlet/oaites?codigo=362824"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["Cancer is a worldwide problem and various cancer therapies are emerging as potential solutions. Among these cancer therapies, a very attractive strategy is that of therapeutic cancer vaccines, which can use tumor-associated peptide fragments that can induce an immune response. In this thesis, we focus on the peptide sequence of MUC1, a glycoprotein presents on the surface of epithelial cells, which leaves simple carbohydrates, and the backbone of the peptide exposed in cancer cells due to aberrant glycosylation. In nature, this exposure to the immune system doesn't trigger a sufficient immune response, due to elusive mechanisms of the cancer cells. For this reason, the core of the present work is to design MUC1-based peptide vaccines modifying the backbone with non-natural mimetics or using different carrier systems to present the antigen to the immune system. In this thesis are presented two vaccines conjugated that have been shown to elicit high immune response utilizing in one case β-amino acid substitutions in the peptide backbone and utilizing as carrier gold nanoparticles, and a second one utilizing an epitope of the MUC1 along with a T helper epitope conjugated to silica nanoparticles. We also present in this work the synthesis of different MUC1 glycopeptides with modifications in the Arg residue and their comparison in terms of affinity towards the SM3 anti-MUC1 monoclonal antibody to select a vaccine candidate among them.","El cáncer es un problema mundial y están surgiendo diversas terapias oncológicas como posibles soluciones. Entre estas terapias contra el cáncer, una estrategia muy actual es la de las vacunas terapéuticas contra el cáncer, que pueden utilizar fragmentos peptídicos asociados al tumor capaces de inducir una respuesta inmunitaria. En esta tesis, trabajaremos con la secuencia peptídica de MUC1, una glicoproteína presente en la superficie de las células epiteliales, que deja expuestos carbohidratos simples y la espina dorsal del péptido en las células cancerosas debido a una glicosilación aberrante. En la naturaleza, esta exposición al sistema inmunitario no desencadena suficiente respuesta inmunitaria para frenar el avance del tumor debido a los mecanismos elusivos de las células cancerosas. Por este motivo, el presente trabajo se centra en diseñar vacunas peptídicas basadas en MUC1 modificando la estructura principal con miméticos no naturales o utilizando diferentes sistemas portadores para presentar el antígeno al sistema inmunitario. En esta tesis se presentan dos vacunas conjugadas que han generado una elevada respuesta inmune utilizando en un caso sustituciones de β-aminoácidos en el esqueleto peptídico y utilizando como sistema portador nanopartículas de oro, y una segunda utilizando un epítopo natural de la MUC1 junto con un epítopo de T helper conjugado con nanopartículas de sílice. También presentamos en este trabajo la síntesis de diferentes glicopéptidos de MUC1 con modificaciones en el residuo Arg y su comparación en términos de afinidad hacia el anticuerpo monoclonal SM3 anti-MUC1 para seleccionar entre ellos un candidato de vacuna."]},{"key":"dc:format","label":"Dc Format","values":["application/pdf"]},{"key":"dc:title","label":"Title","values":["Structure-guided Cancer Vaccines based on Glycopeptides Supported on Diverse Nanoparticles"]}]}],"canonical_facts":{"dc:contributor":["Busto Sancirián, Jesús Héctor (Universidad de La Rioja)","García Martín, Fayna M. (Universidad de La Rioja)"],"dc:creator":["Suárez García, Oscar"],"dc:date":["2025"],"dc:description":["Cancer is a worldwide problem and various cancer therapies are emerging as potential solutions. Among these cancer therapies, a very attractive strategy is that of therapeutic cancer vaccines, which can use tumor-associated peptide fragments that can induce an immune response. In this thesis, we focus on the peptide sequence of MUC1, a glycoprotein presents on the surface of epithelial cells, which leaves simple carbohydrates, and the backbone of the peptide exposed in cancer cells due to aberrant glycosylation. In nature, this exposure to the immune system doesn't trigger a sufficient immune response, due to elusive mechanisms of the cancer cells. For this reason, the core of the present work is to design MUC1-based peptide vaccines modifying the backbone with non-natural mimetics or using different carrier systems to present the antigen to the immune system. In this thesis are presented two vaccines conjugated that have been shown to elicit high immune response utilizing in one case β-amino acid substitutions in the peptide backbone and utilizing as carrier gold nanoparticles, and a second one utilizing an epitope of the MUC1 along with a T helper epitope conjugated to silica nanoparticles. We also present in this work the synthesis of different MUC1 glycopeptides with modifications in the Arg residue and their comparison in terms of affinity towards the SM3 anti-MUC1 monoclonal antibody to select a vaccine candidate among them.","El cáncer es un problema mundial y están surgiendo diversas terapias oncológicas como posibles soluciones. Entre estas terapias contra el cáncer, una estrategia muy actual es la de las vacunas terapéuticas contra el cáncer, que pueden utilizar fragmentos peptídicos asociados al tumor capaces de inducir una respuesta inmunitaria. En esta tesis, trabajaremos con la secuencia peptídica de MUC1, una glicoproteína presente en la superficie de las células epiteliales, que deja expuestos carbohidratos simples y la espina dorsal del péptido en las células cancerosas debido a una glicosilación aberrante. En la naturaleza, esta exposición al sistema inmunitario no desencadena suficiente respuesta inmunitaria para frenar el avance del tumor debido a los mecanismos elusivos de las células cancerosas. Por este motivo, el presente trabajo se centra en diseñar vacunas peptídicas basadas en MUC1 modificando la estructura principal con miméticos no naturales o utilizando diferentes sistemas portadores para presentar el antígeno al sistema inmunitario. En esta tesis se presentan dos vacunas conjugadas que han generado una elevada respuesta inmune utilizando en un caso sustituciones de β-aminoácidos en el esqueleto peptídico y utilizando como sistema portador nanopartículas de oro, y una segunda utilizando un epítopo natural de la MUC1 junto con un epítopo de T helper conjugado con nanopartículas de sílice. También presentamos en este trabajo la síntesis de diferentes glicopéptidos de MUC1 con modificaciones en el residuo Arg y su comparación en términos de afinidad hacia el anticuerpo monoclonal SM3 anti-MUC1 para seleccionar entre ellos un candidato de vacuna."],"dc:format":["application/pdf"],"dc:identifier":["https://dialnet.unirioja.es/servlet/oaites?codigo=362824"],"dc:language":["eng"],"dc:publisher":["Universidad de La Rioja (España)"],"dc:rights":["LICENCIA DE USO: Los documentos a texto completo incluidos en Dialnet son de acceso libre y propiedad de sus autores y/o editores. Por tanto, cualquier acto de reproducción, distribución, comunicación pública y/o transformación total o parcial requiere el consentimiento expreso y escrito de aquéllos. Cualquier enlace al texto completo de estos documentos deberá hacerse a través de la URL oficial de éstos en Dialnet. Más información: https://dialnet.unirioja.es/info/derechosOAI | INTELLECTUAL PROPERTY RIGHTS STATEMENT: Full text documents hosted by Dialnet are protected by copyright and/or related rights. This digital object is accessible without charge, but its use is subject to the licensing conditions set by its authors or editors. Unless expressly stated otherwise in the licensing conditions, you are free to linking, browsing, printing and making a copy for your own personal purposes. All other acts of reproduction and communication to the public are subject to the licensing conditions expressed by editors and authors and require consent from them. Any link to this document should be made using its official URL in Dialnet. More info: https://dialnet.unirioja.es/info/derechosOAI"],"dc:title":["Structure-guided Cancer Vaccines based on Glycopeptides Supported on Diverse Nanoparticles"],"dc:type":["text (thesis)"]},"updated_at":"2026-07-24T06:27:07Z"}